ライフサイエンスコーパス: living donor liver transplantation

1 the first national guideline in the field of living donor liver transplantation.

2 that contribute to biliary complications in living donor liver transplantation.

3 ion were examined and compared with those of living donor liver transplantation.

4 s, the results were comparable with those of living donor liver transplantation.

5 recipient and donor outcomes associated with living donor liver transplantation.

6 carcinoma recurrence has been reported with living donor liver transplantation.

7 , thereby increasing pressures on the use of living donor liver transplantation.

8 parable to those for SD without resorting to living donor liver transplantation.

9 ating to the advantages and disadvantages of living donor liver transplantation.

10 timation of graft volume (GV) is critical in living donor liver transplantation.

11 horts with HCC undergoing either deceased or living donor liver transplantation.

12 rform cadaveric liver transplantation; or 3) living donor liver transplantation.

13 ght ratio of 0.8% is adequate for right lobe living donor liver transplantation.

14 f the different techniques used in pediatric living-donor liver transplantation.

15 done with the "orphan graft" in all cases of living-donor liver transplantation; (2) avoid the premat

16 Preoperative evaluation of donors for living-donor liver transplantation aims to select a suit

17 Adult-to-adult living donor liver transplantation (ALDLT) is being incr

18 BO-incompatible (ABOi) dual-graft (DG) adult living donor liver transplantation (ALDLT) is not common

19 erience in adult-to-adult right hepatic lobe living donor liver transplantation (ALDLT) using extensi

20 er right hepatectomy (RH) for adult-to-adult living donor liver transplantation (ALDLT).

21 bosis (HAT) and patient survival after adult living donor liver transplantation (ALDLT).

22 inical factors to recipient outcome in adult living donor liver transplantation (ALDLT).

23 adaver split liver transplantation and adult living donor liver transplantation and possibly, in the

24 The recipient outcomes with living donor liver transplantation are comparable to tho

25 ords of donors and recipients, who underwent living donor liver transplantation at our institution be

26 a girl with Hardikar syndrome who underwent living-donor liver transplantation at 2 years of age.

27 Adult living donor liver transplantation can be performed safe

28 HCV-infected patients in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL)

29 The Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL)

30 l Institutes of Health-funded Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL),

31 rative complications from the Adult-to-Adult Living Donor Liver Transplantation Cohort study (A2ALL),

32 investigated in the 9-center Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL).

33 were reviewed as part of the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL).

34 nt candidates enrolled in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study after Fe

35 The Adult-to-Adult Living Donor Liver Transplantation Cohort Study is a pro

36 The adult-to-adult living donor liver transplantation cohort study is provi

37 r surgery and enrolled in the Adult-to-Adult Living Donor Liver Transplantation cohort study provides

38 A principal aim of the Adult-to-Adult Living Donor Liver Transplantation Cohort Study was to s

39 ts (963 LDLT) enrolled in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study who rece

40 ansplant were enrolled in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study, includi

41 In the Adult-to-Adult Living Donor Liver Transplantation Cohort Study, patient

42 The advent of living donor liver transplantation for adult recipients

43 The increased recurrence risk with living donor liver transplantation for hepatocellular ca

44 Living donor liver transplantation has become a life-sav

45 Living donor liver transplantation has become an importa

46 Living donor liver transplantation has gained wide accep

47 Living donor liver transplantation has recently been rep

48 Living-donor liver transplantation has helped to allevia

49 The role of living donor liver transplantation in hepatocellular car

50 Clearly, the role of living donor liver transplantation in management of pati

51 Donor selection limits the application of living donor liver transplantation in the adult populati

52 There are limited data on the efficacy of living donor liver transplantation in the setting of HCC

53 ished by liver transplantation, we performed living donor-liver transplantation in an infant with eth

54 Living donor liver transplantation is a viable strategy

55 Adult living donor liver transplantation is being evaluated as

56 A wider application of living donor liver transplantation is limited by donor m

57 Living donor liver transplantation is mainly restricted

58 Living-donor liver transplantation is an accepted techni

59 Some transplant centers have begun offering living donor liver transplantation (LDLT) for selected p

60 Living donor liver transplantation (LDLT) has been contr

61 Early allograft dysfunction (EAD) after living donor liver transplantation (LDLT) has often been

62 /UNOS) data from 2002-2012 to assess whether living donor liver transplantation (LDLT) has surpassed

63 ume, outcomes, uniqueness, and challenges of living donor liver transplantation (LDLT) in Latin Ameri

64 opic approach in right hepatectomy (LRH) for living donor liver transplantation (LDLT) is a controver

65 ty from donation of a right hepatic lobe for living donor liver transplantation (LDLT) is an importan

66 rpose of donor evaluation for adult-to-adult living donor liver transplantation (LDLT) is to discover

67 The data about elderly recipient after living donor liver transplantation (LDLT) is unsatisfact

68 Centers offering adult living donor liver transplantation (LDLT) mostly use rig

69 th hepatocellular carcinoma (HCC) listed for living donor liver transplantation (LDLT) or brain-dead

70 can be used to predict HCC recurrence after living donor liver transplantation (LDLT).

71 rmine the outcome of venous conduits used in living donor liver transplantation (LDLT).

72 More than 2000 adult-to-adult living donor liver transplantations (LDLT) have been per

73 Living-donor liver transplantation (LDLT) has been perfo

74 An important long-term consideration for living-donor liver transplantation (LDLT) is the expense

75 Despite the advantages of living-donor liver transplantation (LDLT), the procedure

76 he most challenging parts of right lobe (RL) living donor liver transplantations (LDLTs).

77 There has been concern that adult living-donor liver transplantation (LLTx) for hepatitis

78 21) and evaluation as a potential donor for living donor liver transplantation (n = 16).

79 was higher than that for the recipients with living donor liver transplantation (P < 0.001).

80 Right lobe living donor liver transplantation poses challenges that

81 Adult living-donor liver transplantation recipients undergo im

82 d a hemodynamic monitoring protocol in adult living-donor liver transplantation recipients, which eva

83 Balancing donor and recipient risks in living donor liver transplantation remains an issue of d

84 Data from the 9-center Adult-to-Adult Living Donor Liver Transplantation retrospective cohort

85 Living-donor liver transplantation should confer a subst

86 to primary or metastatic liver tumors, or in living donor liver transplantation, strategies to quell

87 We report two cases of adult to adult living donor liver transplantation using a right hepatic

88 Donor selection criteria for adult-to-adult living donor liver transplantation vary with the medical

89 itish Transplantation Society Guidelines for Living Donor Liver Transplantation was published in July

90 Living-donor liver transplantation was the best strategy

91 d PVP is associated with liver failure after living donor liver transplantation, we hypothesized that